Expertise in
3
conditions

Dr. Susannah Cooper

Hematology
2070 W Rudasill Rd Ste 130, 
Tucson, AZ 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
2070 W Rudasill Rd Ste 130, 
Tucson, AZ 

Overview

Susannah Cooper is a Hematologist practicing medicine in Tucson, Arizona.

Dr. Cooper is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses HER-2 Positive Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Triple-Negative Breast Cancer.

Dr. Cooper is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 10 clinical trials. Dr. Cooper is currently accepting new patients.

Graduate Institution

Uniformed Services University Of The Health Scienc

Residency

National Naval Medical Center

Specialties

Hematology

Licenses

Internal Medicine in TX

Board Certifications

American Board Of Internal Medicine

Fellowships

San Antonio Uniformed Services Health Education Co

Hospital Affiliations

Centra Bedford Memorial Hospital
Centra Health - Lynchburg Gen Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Moda Health
  • EPO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Arizona Oncology Associates
2070 W Rudasill Rd Ste 130, Tucson, AZ 85704
Other Locations
Arizona Oncology Associates
2625 N Craycroft Rd Ste 100, Tucson, AZ 85712
Arizona Oncology Associates
1315 S La Canada Dr, Green Valley, AZ 85622
Arizona Oncology Associates
1620 W Saint Marys Rd, Tucson, AZ 85745

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.
Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.
Journal: Case reports in oncological medicine
Published: April 13, 2016
Similar Doctors
Expertise in
11
conditions
Dr. Jonathan Schwartz
Hematology | Oncology
Expertise in
11
conditions
Dr. Jonathan Schwartz
Hematology | Oncology

Arizona Blood And Cancer Specialists PLLC

3700 E Fort Lowell Rd Ste 130, 
Tucson, AZ 
 (1827.0 miles away)
520-881-0631
Languages Spoken:
English
See accepted insurances

Jonathan Schwartz is a Hematologist and an Oncologist practicing medicine in Tucson, Arizona. Dr. Schwartz is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Breast Cancer.

Expertise in
51
conditions
Dr. Ian Deroock
Hematology
Expertise in
51
conditions
Dr. Ian Deroock
Hematology

Ironwood Physicians

1637 E Monument Plaza Cir Ste 1, 
Casa Grande, AZ 
 (1856.4 miles away)
480-961-2323
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Deroock is a Hematologist practicing medicine in Casa Grande, Arizona. Dr. Deroock is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Pulmonary Embolism, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia. Dr. Deroock is board certified in American Board Of Internal Medicine. Dr. Deroock is currently accepting new patients.

Expertise in
9
conditions
Dr. Natalie Stanton
Hematology | Oncology
Expertise in
9
conditions
Dr. Natalie Stanton
Hematology | Oncology

Arizona Blood And Cancer Specialists PLLC

3700 E Fort Lowell Rd Ste 130, 
Tucson, AZ 
 (1827.0 miles away)
520-881-0631
Languages Spoken:
English
See accepted insurances

Natalie Stanton is a Hematologist and an Oncologist practicing medicine in Tucson, Arizona. Dr. Stanton is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Eccrine Porocarcinoma, and Lynch Syndrome.

Frequently Asked Questions about Dr. Susannah Cooper

How do I make an appointment with Dr. Susannah Cooper?

You can book an appointment with Dr. Susannah Cooper by calling their office at 520-797-4468. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susannah Cooper a top-rated expert for HER-2 Positive Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susannah Cooper is classified as an Advanced expert for HER-2 Positive Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susannah Cooper specialize in?

While Dr. Susannah Cooper is a Hematology, they have specific expertise in HER-2 Positive Breast Cancer, Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Susannah Cooper participate in research or clinical trials?

Yes. Dr. Susannah Cooper has published 1 articles and abstracts on conditions like HER-2 Positive Breast Cancer. You can view a list of Dr. Susannah Cooper's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susannah Cooper accept my insurance?

Dr. Susannah Cooper accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 520-797-4468 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooper's expertise for a condition
ConditionClose
      View All 116 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile